Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

275 results about "Emerin" patented technology

Emerin is a protein that in humans is encoded by the EMD gene, also known as the STA gene. Emerin, together with LEMD3, is a LEM domain-containing integral protein of the inner nuclear membrane in vertebrates. Emerin is highly expressed in cardiac and skeletal muscle. In cardiac muscle, emerin localizes to adherens junctions within intercalated discs where it appears to function in mechanotransduction of cellular strain and in beta-catenin signaling. Mutations in emerin cause X-linked recessive Emery–Dreifuss muscular dystrophy, cardiac conduction abnormalities and dilated cardiomyopathy.

Fusion proteins

A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the dynorphin Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.
Owner:HEALTH PROTECTION AGENCY +1

Producing process of sterile plants, plants obtained by the process, and use of the plants

InactiveUS20110099664A1Suppress transcriptionReliable and easy to produceOther foreign material introduction processesFermentationDouble-floweredPlant cell
Transcription of a gene associated with formation of floral organs is suppressed to produce a sterile plant. A plant cell is transfected with a chimeric gene that includes (i) a coding gene of a transcription factor that promotes expression of a gene associated with formation of floral organs, and (ii) a polynucleotide that encodes a functional peptide that converts an arbitrary transcription factor into a transcription repressor, and a chimeric protein in which the transcription factor is fused with the functional peptide is expressed in the plant cell. The expression of the gene associated with formation of floral organs is dominantly suppressed by the chimeric protein, and as a result a male sterile plant is produced that cannot properly form pollen. The chimeric protein also suppresses expression of a gene associated with dehiscence of anther, and as a result a plant is produced in which dehiscence of anther is suppressed. Further, the chimeric protein suppresses expression of target genes of a transcription factor associated with formation of stamen and pistil, and as a result a double flowered plant is produced.
Owner:NAT INST OF ADVANCED IND SCI & TECH

Methods and compositions for treating brain diseases

The present disclosure provides methods of treating a disease in a non-rodent mammal comprising administering to the cerebrospinal fluid (CSF) of the non-rodent mammal an rAAV2 particle containing a vector comprising a nucleic acid encoding a therapeutic protein inserted between a pair of AAV inverted terminal repeats in a manner effective to infect an ependymal cell in the non-rodent mammal, wherein the ependymal cell secretes the therapeutic protein so as to treat the disease.
Owner:UNIV OF IOWA RES FOUND

Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions

InactiveUS20160376328A1Reduces and eliminates cytotoxicityFacilitates cellular internalizationAntibacterial agentsPeptide/protein ingredientsCellular pathwaysCytotoxicity
The present invention provides proteins comprising immunoglobulin-type binding regions for cell-type specific targeting and Shiga toxin A Subunit effector regions for Shiga toxin effector functions (e.g. cellular internalization, directing subcellular routing, and / or cytotoxicity), wherein the binding regions and Shiga toxin effector regions are combined such that the Shiga toxin effector regions are proximal to the amino-terminals of the proteins. The presently disclosed proteins can comprise additional exogenous materials, such as, e.g., antigens, cytotoxic agents, and detection-promoting agents, and are capable of targeted delivery of these additional exogenous materials into the interiors of target cells. The proteins of the present invention have uses in methods such as, e.g., methods involving targeted killing of target cells, delivering exogenous materials into target cells, labeling subcellular compartments of target cells, and diagnosing and / or treating a variety of conditions including cancers, tumors, other growth abnormalities, immune disorders, and microbial infections.
Owner:MOLECULAR TEMPLATES

Immunogenic composition and method of developing a vaccine based on fusion protein

The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to HIV fusion protein. The present invention contemplates three categories of embodiments: protein or protein fragments, messenger RNA, or DNA / RNA. DNA / RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.
Owner:KARP NELSON M
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products